[go: up one dir, main page]

WO2009083612A3 - Flavonoïdes utilisés comme agents prophylactiques et thérapeutiques contre des maladies neurodégénératives et d'autres maladies liées à un repliement aberrant de protéines - Google Patents

Flavonoïdes utilisés comme agents prophylactiques et thérapeutiques contre des maladies neurodégénératives et d'autres maladies liées à un repliement aberrant de protéines Download PDF

Info

Publication number
WO2009083612A3
WO2009083612A3 PCT/EP2009/050020 EP2009050020W WO2009083612A3 WO 2009083612 A3 WO2009083612 A3 WO 2009083612A3 EP 2009050020 W EP2009050020 W EP 2009050020W WO 2009083612 A3 WO2009083612 A3 WO 2009083612A3
Authority
WO
WIPO (PCT)
Prior art keywords
aberration
diseases
disease
protein folding
neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/050020
Other languages
German (de)
English (en)
Other versions
WO2009083612A2 (fr
Inventor
Martin H. Groschup
Martin Eiden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2009083612A2 publication Critical patent/WO2009083612A2/fr
Publication of WO2009083612A3 publication Critical patent/WO2009083612A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne l'utilisation de flavonoïdes d'origine synthétique ou végétale, de leurs dérivés ou produits de dégradation pour le traitement thérapeutique et prophylactique de maladies liées à une agrégation et à un repliement aberrant de protéines. L'invention concerne en particulier des préparations à base de scutellaire et de plantes contenant des extraits similaires (telles que le persil, le céleri, la camomille et les chrysanthèmes) et à base des extraits contenus dans ces plantes, utilisés purs ou en associations (y compris les substances connues telles que baicaléine, baicaline, etc.) comme substances à efficacité thérapeutique et/ou prophylactique contre des infections à prions et d'autres maladies neurodégénératives liées à un repliement aberrant de protéines (telles la maladie d'Alzheimer, la maladie de Parkinson, la maladie de Huntington, l'amylose sénile, les tauopathies, etc.) chez l'homme et l'animal.
PCT/EP2009/050020 2008-01-02 2009-01-02 Flavonoïdes utilisés comme agents prophylactiques et thérapeutiques contre des maladies neurodégénératives et d'autres maladies liées à un repliement aberrant de protéines Ceased WO2009083612A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008003467A DE102008003467A1 (de) 2008-01-02 2008-01-02 Flavonoide als Mittel zur Prophylaxe und Behandlung von neurodegenerativen und anderen Proteinfehlfaltungskrankheiten
DE102008003467.3 2008-01-02

Publications (2)

Publication Number Publication Date
WO2009083612A2 WO2009083612A2 (fr) 2009-07-09
WO2009083612A3 true WO2009083612A3 (fr) 2009-11-26

Family

ID=40640276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/050020 Ceased WO2009083612A2 (fr) 2008-01-02 2009-01-02 Flavonoïdes utilisés comme agents prophylactiques et thérapeutiques contre des maladies neurodégénératives et d'autres maladies liées à un repliement aberrant de protéines

Country Status (2)

Country Link
DE (1) DE102008003467A1 (fr)
WO (1) WO2009083612A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101700016B1 (ko) * 2011-12-26 2017-01-26 모리나가 뉴교 가부시키가이샤 근위축 억제제
CN103845377A (zh) * 2012-12-06 2014-06-11 新疆比尔兄弟生物技术有限公司 一种连续逆流超声波提取洋甘菊总黄酮的方法
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use
CN116270602B (zh) * 2023-03-03 2025-06-27 上海交通大学医学院 小分子化合物2-d08在制备治疗或预防脱髓鞘疾病药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080590A1 (fr) * 2005-01-25 2006-08-03 University-Industry Cooperation Group Of Kyung Hee University Composition comprenant l'extrait d'un complexe de medicament brut a activite neuroprotectrice pour la prevention et le traitement d'accidents cerebro-vasculaires et de maladie neurodegeneratives
WO2007038610A2 (fr) * 2005-09-26 2007-04-05 President & Fellows Of Harvard College Utilisation de produits naturels pour le traitement de troubles neurologiques
EP1808169A2 (fr) * 1999-12-30 2007-07-18 Proteotech Inc. Composés aromatiques polyhydroxylés pour le traitement des maladies fibrilles d'amylose et alpha-synucléines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087567A2 (fr) * 2001-05-02 2002-11-07 Kgk Synergize Inc. Utilisation de flavones polymethoxylees afin de traiter l'insulinoresistance

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1808169A2 (fr) * 1999-12-30 2007-07-18 Proteotech Inc. Composés aromatiques polyhydroxylés pour le traitement des maladies fibrilles d'amylose et alpha-synucléines
WO2006080590A1 (fr) * 2005-01-25 2006-08-03 University-Industry Cooperation Group Of Kyung Hee University Composition comprenant l'extrait d'un complexe de medicament brut a activite neuroprotectrice pour la prevention et le traitement d'accidents cerebro-vasculaires et de maladie neurodegeneratives
WO2007038610A2 (fr) * 2005-09-26 2007-04-05 President & Fellows Of Harvard College Utilisation de produits naturels pour le traitement de troubles neurologiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN XIN ET AL: "[Protective effect of baicalin on mouse with Parkinson's disease induced by MPTP]", ZHONGGUO ZHONG XI YI JIE HE ZA ZHI ZHONGGUO ZHONGXIYI JIEHE ZAZHI = CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE / ZHONGGUO ZHONG XI YI JIE HE XUE HUI, ZHONGGUO ZHONG YI YAN JIU YUAN ZHU BAN NOV 2007, vol. 27, no. 11, November 2007 (2007-11-01), pages 1010 - 1012, XP009118091, ISSN: 1003-5370 *
DATLA K P ET AL: "Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease.", NEUROREPORT 4 DEC 2001, vol. 12, no. 17, 4 December 2001 (2001-12-04), pages 3871 - 3875, XP009073296, ISSN: 0959-4965 *
PORAT Y ET AL: "Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interaction as a common inhibition mechanism", CHEMICAL BIOLOGY & DRUG DESIGN, BLACKWELL PUBLISHING TD., OXFORD, GB, vol. 67, 1 January 2006 (2006-01-01), pages 27 - 37, XP003016012, ISSN: 1747-0277 *

Also Published As

Publication number Publication date
WO2009083612A2 (fr) 2009-07-09
DE102008003467A1 (de) 2009-09-10

Similar Documents

Publication Publication Date Title
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
WO2012080729A3 (fr) Inhibiteurs de caséine kinase 1δ (ck1δ)
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
WO2006103037A3 (fr) Composition contenant la $g(b)-defensine 2
IL206945A (en) Compounds used as modulators of amyloid beta, the process for their preparation and drugs containing them, for the treatment of Alzheimer's disease
BRPI0924460A2 (pt) composição farmacêutica para uso em oftalmologia médica e veterinária
CL2013001436A1 (es) Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel.
CL2012001336A1 (es) Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas.
WO2006075330A3 (fr) Procedes et compositions pharmaceutiques utilisees pour le traitement du psoriasis
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
MX2009011869A (es) Aislados antimicrobianos y anti-inflamatorios de extracto de regaliz.
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
WO2007106617A3 (fr) Procede de traitement et prophylaxie utilisant l'immunoglobuline m
CL2007003480A1 (es) Compuestos derivados de tiazolo[5,4-c]piridin-4-ona sustituida; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento o prevencion de enfermedades relacionadas con la obesidad, como trastornos de la alimentacion, diab
BRPI0814864A2 (pt) Utilização de uma quantidade eficaz de hesperidina ou um de seus derivados e processo cosmético de tratamento e/ou prevenção das peles flácidas e/ou estrias.
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
CL2012001940A1 (es) Composiciones que comprenden extractos de andrographis paniculata combinados con extractos de ginkgo biloba complejados con fosfolípidos; y su uso en la preparación de un medicamento para el tratamiento de alzheimer y esclerosis múltiple.
WO2011043631A3 (fr) Composition pharmaceutique pour la prévention et le traitement du rhume, contenant un extrait de reynoutria elliptica, une fraction de celui-ci ou un composé à base de stilbène
WO2009083612A3 (fr) Flavonoïdes utilisés comme agents prophylactiques et thérapeutiques contre des maladies neurodégénératives et d'autres maladies liées à un repliement aberrant de protéines
CL2007003190A1 (es) Compuestos derivados de arilsulfonil-pirrolidinas; procedimiento de obtencion; composicion farmaceutica; y uso en la prevencion o tratamiento de enfermedades tales como psicosis, depresion, alzheimer, entre otras.
HUP0300732A2 (hu) Chlamydiás fertżzések kezelésében és megelżzésében hatékony növényi-eredetż és szintetikus fenolos vegyületek és növényi extraktumok
BRPI0922870A2 (pt) uso de ao menos um composto da fórmula i, do compsoto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético
IL196606A (en) Use of Eskin for the preparation of medical preparations and medical preparations containing Eskin for the treatment of diseases
CL2008000982A1 (es) Compuestos derivados de 5-oxo-isoxazol-carboxamida; proceso de preparacion; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09700143

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09700143

Country of ref document: EP

Kind code of ref document: A2